Timeliness and actionable intelligence over I-Banks research which remains only geared to institutional investors and legacy processes. News carries with it a promise of transparency, a light that can be shined into previously dark corners.
But they don’t define any relevance to the actual value of a release - mostly due to SEC forward looking parameters. However, this news portal has been expanded to … supplement, measure and price the event and relevance to a company’s ... valuation.
November 7, 2018
Quarterly (Q3) results special: ATHX, BOLD, BLCM and GBT
November 6, 2018
Quarterly (Q3) results special: IONS, ONCE, QURE and VCEL
September 11, 2018
Regenerative Medicine Earnings Scorecard - Q2/18 - to date
August 17, 2018
Gene editing stocks, time to harvest some upside?
April 4, 2018
Cellectis (CLLS) prices follow-on $175 M ADS offering
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at firstname.lastname@example.org.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors